Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GlaxoSmithKline has released data showing that a vaccine it is developing for H5N1 avian flu achieved a high immune response at a low dose. Interim analysis of a clinical trial found that more than 80% of subjects who received a 3.8-mg dose of active ingredient demonstrated a "strong" immune response. The vaccine includes a proprietary response-boosting adjuvant. CEO Jean-Pierre Garnier says GSK expects to make a regulatory filing for the vaccine "in the coming months." Sanofi Pasteur reported in May on a developmental vaccine that was effective in two-thirds of patients at a 30-mg dose but in only about 40% of patients at a 7.5-mg dose.
This article has been sent to the following recipient: